Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neostigmine and Glycopyrrolate for Post Dural Puncture Headache
NCT05116930Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Nov 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of neostigmine in post-dural puncture headache (PDPH), sponsored by Mayo Clinic. Primary endpoint: Number of postpartum women requiring epidural blood patch at 2 weeks. Started Nov 2021; status: recruiting.
02
Drugs
neostigmine
03
Conditions
post-dural puncture headache (PDPH)
Beyond the preview
Go deeper on NCT05116930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116930.